Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)
Clinical trial NCT02368951 · TERMINATED
Trial details
- NCT number
- NCT02368951
- Sponsor
- Bayer
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-03-24
- Primary completion
- 2016-07-27
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.